参麦注射液对老年肺癌合并Ⅱ型糖尿病患者的免疫功能影响

摘要

目的：本研究旨在观察参麦注射液对老年肺癌合并Ⅱ型糖尿病患者治疗过程中免疫功能的影响，以评价参麦注射液对此类患者的临床药物价值。方法：将42例符合标准的入院患者随机分成两组，实验组在放化疗治疗过程中给予参麦注射液，对照组单纯进行放化疗。两组的放化疗方案一致。分别在治疗开始以及治疗完成后3周对患者进行T细胞亚群检测。治疗前后同时对两组进行 K PS评分比较。结果：对照组CD3、CD4、CD4／CD8显著降低（ P＜0.05），而CD8显著升高（ P＜0．05）；实验组CD3、CD4、CD4／CD8升高，尤其对于治疗有效者差异具有显著性。并且实验组K PS评分较治疗前显著升高。结论：参麦注射液可以提高老年肺癌合并Ⅱ型糖尿病患者的免疫功能，从而对治疗效果及患者的生存质量起到促进作用。%Objective :This research is to observe the immunity state of aging lung cancer combined with type Ⅱ diabe‐tes mellitus by Shenmai injection ,and to evaluate the clinic medicine value .Methods :Forty‐two admission patients who fitted to the standard have been falled into two groups .The experimental group have been given Shenmai injection com‐bined with chemoradiation ,but the control group just only have been give chemoradiation .All the two groups were car‐ried out T‐cell subgroup experiment at the beginning and three weeks after the therapy .At the same time ,we appraise the KPS scores of the two groups .Results:After therapy CD3 ,CD4 and CD4/CD8 all indicates significant lower level (P<0 .05)in the group of simple radiotherapy in sync with chemotherapy .But in the group of radiotherapy in sync with chemotherapy combined with Shenmai injection CD3 ,CD4 and CD4/CD8 all indicates higher lever after the therapy ,es‐pecially to the CR and PR patients (P<0 .05) .And in the experimental group ,the patients had higher KPS scores after therapy(P<0 .05) .Conclusion:Shenmai injection can enhance the immune function of the organism ,meanwhile can im‐prove treatment effectiveness the existence quality .